Surprisingly, no differences were observed in PlexiQoL scores between participants with and without treatment, despite that more severe cases of NF1-associated plexiform neurofibroma tend to be treated with pain medication or MEK-inhibitors. This evidence concerns the gene MAP2K7 and plexiform neurofibroma.